Lisa Gallicchio1,2,3, Carla Calhoun4, Kathy Helzlsouer5,6. 1. Epidemiology and Genomics Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, 9609 Medical Center Drive, Rockville, MD, 20850, USA. lisagallicchio@gmail.com. 2. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, 21205, USA. lisagallicchio@gmail.com. 3. Department of Epidemiology and Public Health, University of Maryland, Baltimore, Baltimore, MD, 21201, USA. lisagallicchio@gmail.com. 4. National Institutes of Health Clinical Center, 10 Center Drive, Bethesda, MD, 20814, USA. 5. Epidemiology and Genomics Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, 9609 Medical Center Drive, Rockville, MD, 20850, USA. 6. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, 21205, USA.
Abstract
PURPOSE: The objective of this study was to examine the associations between aromatase inhibitors (AIs) and side effects less frequently reported in the literature, including difficulty concentrating, forgetfulness, hair loss, and numbness in the extremities. METHODS: Data were analyzed from a cohort of 146 breast cancer patients initiating AI therapy and followed for 1 year and a cohort of 144 postmenopausal women without a history of cancer followed for 6 months. At baseline (prior to AI therapy for breast cancer patients), and at 3 months, 6 months, and 1 year (for breast cancer patients only), a comprehensive questionnaire was administered that ascertained data on symptoms. Odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated using logistic regression for new onset of symptoms among the breast cancer patients compared to the women without a history of cancer. RESULTS: Among the breast cancer patients, 34.2% were treated with chemotherapy prior to AI treatment. Over the first 6 months of AI treatment, breast cancer patients had significantly higher odds of reporting new onset of forgetfulness (OR 4.00; 95% CI 1.67, 9.59), difficulty concentrating (OR 2.73; 95% CI 1.29; 5.78), hair loss (OR 4.12; 95% CI 1.86, 9.17), and numbness/tingling in the extremities (OR 2.47; 95% CI 1.09, 5.62) compared to women without a history of cancer. Similar increases in odds were observed for the subgroup of women not treated with chemotherapy versus the comparison group. CONCLUSIONS: AI-related symptoms should be monitored and addressed so that adherence to therapy is maintained.
PURPOSE: The objective of this study was to examine the associations between aromatase inhibitors (AIs) and side effects less frequently reported in the literature, including difficulty concentrating, forgetfulness, hair loss, and numbness in the extremities. METHODS: Data were analyzed from a cohort of 146 breast cancerpatients initiating AI therapy and followed for 1 year and a cohort of 144 postmenopausal women without a history of cancer followed for 6 months. At baseline (prior to AI therapy for breast cancerpatients), and at 3 months, 6 months, and 1 year (for breast cancerpatients only), a comprehensive questionnaire was administered that ascertained data on symptoms. Odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated using logistic regression for new onset of symptoms among the breast cancerpatients compared to the women without a history of cancer. RESULTS: Among the breast cancerpatients, 34.2% were treated with chemotherapy prior to AI treatment. Over the first 6 months of AI treatment, breast cancerpatients had significantly higher odds of reporting new onset of forgetfulness (OR 4.00; 95% CI 1.67, 9.59), difficulty concentrating (OR 2.73; 95% CI 1.29; 5.78), hair loss (OR 4.12; 95% CI 1.86, 9.17), and numbness/tingling in the extremities (OR 2.47; 95% CI 1.09, 5.62) compared to women without a history of cancer. Similar increases in odds were observed for the subgroup of women not treated with chemotherapy versus the comparison group. CONCLUSIONS: AI-related symptoms should be monitored and addressed so that adherence to therapy is maintained.
Entities:
Keywords:
Aromatase inhibitors; Breast cancer; Cognitive dysfunction; Hair loss; Neuropathy
Authors: R C Coombes; L S Kilburn; C F Snowdon; R Paridaens; R E Coleman; S E Jones; J Jassem; C J H Van de Velde; T Delozier; I Alvarez; L Del Mastro; O Ortmann; K Diedrich; A S Coates; E Bajetta; S B Holmberg; D Dodwell; E Mickiewicz; J Andersen; P E Lønning; G Cocconi; J Forbes; M Castiglione; N Stuart; A Stewart; L J Fallowfield; G Bertelli; E Hall; R G Bogle; M Carpentieri; E Colajori; M Subar; E Ireland; J M Bliss Journal: Lancet Date: 2007-02-17 Impact factor: 79.321
Authors: John F Forbes; Jack Cuzick; Aman Buzdar; Anthony Howell; Jeffrey S Tobias; Michael Baum Journal: Lancet Oncol Date: 2008-01 Impact factor: 41.316
Authors: Jacquie H Chirgwin; Anita Giobbie-Hurder; Alan S Coates; Karen N Price; Bent Ejlertsen; Marc Debled; Richard D Gelber; Aron Goldhirsch; Ian Smith; Manuela Rabaglio; John F Forbes; Patrick Neven; István Láng; Marco Colleoni; Beat Thürlimann Journal: J Clin Oncol Date: 2016-05-23 Impact factor: 44.544
Authors: Kunal C Kadakia; Claire F Snyder; Kelley M Kidwell; Nicholas J Seewald; David A Flockhart; Todd C Skaar; Zereunesay Desta; James M Rae; Julie L Otte; Janet S Carpenter; Anna M Storniolo; Daniel F Hayes; Vered Stearns; N Lynn Henry Journal: Oncologist Date: 2016-03-23
Authors: Yunxin He; Eng Hooi Tan; Andrea Li Ann Wong; Chuan Chien Tan; Patrick Wong; Soo Chin Lee; Bee Choo Tai Journal: BMC Cancer Date: 2018-07-09 Impact factor: 4.430